FDA Decision On Tolebrutinib MStranslate January 12, 2026 Clinical Trials Last week, we posted on Facebook that the FDA has decided to not approve tolebrutinib for the treatment of secondary progressive multiple sclerosis, despite positive Phase 3 trial results. In this article,...
Multiple Sclerosis Research In 2026 MStranslate January 5, 2026 Progressive MS, Remyelination, Treatments 2026 is upon us! As fireworks ring out around the world to usher in the new year, we like to look ahead and think about what new developments we might see in multiple sclerosis research over the coming 12...
